The Future of Obesity Treatment: Pfizer's Vision for a Healthier Tomorrow

In a major blow to Pfizer's obesity drug pipeline, the pharmaceutical giant has discontinued its once-daily oral GLP-1 receptor agonist, danuglipron. The move follows a clinical trial in which a patient had a possible drug-induced liver injury, even though the patient's liver enzymes normalized upon stopping the drug.

Key Highlights:

Liver Injury Event: One patient had raised liver enzymes, which normalized upon discontinuation of danuglipron. Liver injury led to an extensive review of clinical information and regulatory comments, and Pfizer discontinued the drug development process.

Market Impact: Pfizer's abandonment of the danuglipron project is a significant setback in its efforts to compete with Eli Lilly and Novo Nordisk for dominance in the fast-growing GLP-1 market, which is expected to hit $150 billion by the early 2030s.

Ongoing Obesity Research: Pfizer continues to work on other obesity drugs, such as an oral GIPR antagonist, which is in phase 2 trials. The company reaffirms its commitment to the advancement of innovative therapies for unmet medical needs.

Pfizer's action highlights the difficulty of creating safe and effective oral GLP-1 drugs, a market that is dominated by injectable drugs. In spite of this failure, Pfizer's continued research into obesity drugs shows its dedication to solving this serious health problem.

Source: CNBC, Business Wire, Bloomberg